Physician

Alcohol Addiction Treatment Firm will be Banned from Disclosing Health Data for Advertising to Settle FTC Charges that It Shared Data Without Consent

Retrieved on: 
Friday, April 12, 2024
GoodRx, Consumer protection, Accountability Act, District court, Meta, Social media, Blog, News, Disclosure, DOJ, Commission, HIPAA, Complaint, Data collection, Advertising, IP, Justice, BetterHelp, API, File, Monument, Privacy, Government, Physician, IDS, Federal Trade Commission, FTC

The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.

Key Points: 
  • The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.
  • As part of a proposed order settling the FTC allegations, New York-based Monument, Inc. will be banned from disclosing health information for advertising and must obtain users’ affirmative consent before sharing health information with third parties for any other purpose.
  • “This action continues the FTC’s work to ensure strict limits on how firms handle sensitive health data, rather than putting the onus on consumers to protect themselves,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection.
  • Monument used these pixels and APIs to track “standard” and “custom events,” meaning instances in which consumers interacted with Monument’s website.
  • If the company is found to have misrepresented its finances, it will be required to pay the full amount.
  • The Commission voted 3-0 to refer the complaint and stipulated final order to the Department of Justice for filing.
  • The DOJ filed the complaint and stipulated order in the U.S. District Court for the District of Columbia.

EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Wednesday, April 10, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

EQS-News: APONTIS PHARMA expects profitable growth again in 2024

Retrieved on: 
Wednesday, April 10, 2024
EUR, Annual report, Tax, Marketing, Ticker, Growth, Physician, Depreciation, Pharmaceutical industry

APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).

Key Points: 
  • APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “The 2023 financial year was characterized by significant changes for APONTIS PHARMA.
  • Following the successful implementation of the performance and efficiency improvement program earlier than planned, APONTIS PHARMA has laid the foundations for future profitable growth in Single Pill combinations.
  • As such, we launched our 15th Single Pill combination on the German market in March and continue to see considerable growth potential for Single Pill combinations from APONTIS PHARMA.

EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, April 10, 2024
Gene expression, Colorectal cancer, Partnership, Patient, Biomarker, Gold, Pivotal, Messenger, Oncology, Science, PMA, CRC, EOL, Marketing, FDA, Physician, Quest Diagnostics, Vaccine

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million

Key Points: 
  • ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million
    BERKELEY, US – MAINZ, Germany – April 9, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023.
  • “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer (CRC) detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Final preparations for Pivotal FDA PMA clinical trial (ReconAAsense) evaluating gold standard self-administered CRC test - on track to commence patient enrollment in 2024.
  • Established commercial operations in major markets including Spain, Poland, Romania, Portugal, Israel, and the UK.

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
Wednesday, April 10, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
Monday, April 8, 2024
CASA, Toothpaste, Head, Confusion, Tooth brushing, EFP, Journal of Clinical Periodontology, Patient, Quality of life, Complutense University of Madrid, UCM, Therapy, Dental, Oral hygiene, Etiology, United States of Europe, Risk, Education, Gingivitis, Treatment, Recurrence, Dentistry, Prevalence, Disease, Clinical, White paper, Public, Knowledge, Research, University, Overalls, University College London, Mouthwash, Dentist, Molina Healthcare, Health, Motivation, Incidence, Physician, British Dental Journal, Inflammation, Pharmacist, Plaque, Systematic review, Bleeding, S3, Meta-analysis

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Oberheiden P.C. Welcomes Former Federal Prosecutor Jennifer W. Corinis as New Litigation Counsel

Retrieved on: 
Friday, March 15, 2024
Bachelor of Arts, Knowledge, False Claims Act, Wellesley College, Fraud, Medicare, Government, Physician, Private investigator

, a premier Dallas-based litigation and compliance firm, proudly announces the addition of Jennifer W. Corinis to its team as Litigation Counsel.

Key Points: 
  • , a premier Dallas-based litigation and compliance firm, proudly announces the addition of Jennifer W. Corinis to its team as Litigation Counsel.
  • With a distinguished 25-year career that spans across various sectors of the legal system, Corinis brings a wealth of experience and expertise, particularly in federal civil and criminal litigation, as well as appeals.
  • Before joining Oberheiden P.C., Jennifer W. Corinis dedicated 14 years of her career to serving as a federal prosecutor, where she honed her skills in the courtroom, successfully trying a dozen federal cases on behalf of the United States and arguing numerous cases before the United States Court of Appeals.
  • Throughout her illustrious career, Corinis has achieved notable successes in defending federal agencies, companies, and individuals in high-stakes litigation.

Neusoft Xikang Holdings Inc. Releases 2023 Annual Results, Business Structure Gradually Optimized, Share of Medical Services Business Continued to Grow

Retrieved on: 
Wednesday, March 20, 2024
Online, Home care, Health, Physician, Patient, Hospital, Health care, City, Nursing, Government

In 2023, internet medical services were more widely recognized and developed rapidly, and digital healthcare services are becoming a regularised healthcare option for the public.

Key Points: 
  • In 2023, internet medical services were more widely recognized and developed rapidly, and digital healthcare services are becoming a regularised healthcare option for the public.
  • In 2023, online medical services provided by city-level online hospitals in Ningbo accounted for 53% of the total services in the city.
  • At the same time, the Group continued to optimize the medical service process, constantly diversified scenarios and content of online medical services, leading to a significant increase in customer services.
  • The focus will be on the coordinated development of "Medical + Nursing + Health" service business, providing users with more sustainable, convenient, and high-quality medical and health services.

Food & Society at the Aspen Institute Releases the 2024 Food is Medicine Research Action Plan

Retrieved on: 
Tuesday, April 9, 2024
Emory University, Organization, Conference, Walmart, Policy, Associated, Health equity, Diabetes, Senior lecturer, Aspen, Research, Prescription, Doctor of Philosophy, Quality of life, White House conference, Society, Nutrition, University of Massachusetts, Aspen Institute, Physician, Meal, Dietary supplement

Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.

Key Points: 
  • Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.
  • It is the first report to pull together the latest peer-reviewed Food is Medicine research in a digestible, comprehensible, and action-oriented format.
  • Associated health outcomes like diabetes and heart disease remain far greater among Black and Latinx individuals and households.
  • Like the original, the revised version of the Research Action Plan has been made possible thanks to the continuing support of the Walmart Foundation.